Introduction
Ovarian cancer is the fifth most common form of cancer in women (Bonome et al., 2008) , and it has the worst prognosis of all gynecological malignancies in the United States, Europe and Japan (Takemoto et al., 2004; Takano et al., 2006) . Epithelial ovarian cancers are thought to develop from deregulation of cells within the ovarian surface epithelia and differentiate into four major histological subtypes: serous (OS), mucinous (OM), endometrioid (OE) adenocarcinomas and ovarian clear cell carcinomas (OCCCs) during malignant transformation. Recent reports also indicate that ovarian cancers, especially of clear cell and endometrioid histologies, arise from endometriotic epithelial cells in endometriosis (Dinulescu et al., 2005; Marquez et al., 2005) . Increasing evidence suggests that development of various subtypes of ovarian cancer is attributable to different etiologies, although the precise molecular processes have not yet been fully elucidated (Cheng et al., 2005; Dinulescu et al., 2005) . OCCC has clinical characteristics and behavior that are distinct from the other major histological types of epithelial ovarian cancer (Skirnisdottir et al., 2005) : OCCC is often associated with endometriosis, is often accompanied by a thromboembolic complication, its clinical outcome in advanced stage is generally poor and it is relatively resistant to chemotherapy (Sugiyama et al., 2000; Chan et al., 2008; Itamochi et al., 2008) . These findings suggest that OCCC has distinct genetic background that may require individualized treatment modality for OCCC.
We previously reported that the contents of endometriotic cysts, especially the high concentration of free iron in these cysts, promote carcinogenesis through ironinduced persistent oxidative stress (Yamaguchi et al., 2008) . Our report was the first to show a relationship between iron and ovarian cancer development in endometriosis. We also showed that OCCC cells can survive under conditions of high oxidative stress, suggesting that the cells encountering persistent oxidative stress in vivo in the unique environment of the endometriotic cyst may acquire such characteristics potentially leading to carcinogenesis.
Microarray analysis of tumor samples is a powerful tool for the development of profiles that can distinguish, identify and classify discrete subsets of disease and predict disease outcome or the response to therapy in various cancers, such as breast, bladder, lung, colon or hematopoietic malignancies (Ito et al., 2007; GarciaEscudero and Paramio, 2008) . Recent microarray analyses enabled us to compare not only the expression of genes with respect to different phenotypes, but also to evaluate biological functions, such as oncogenic signaling pathway activity (Bild et al., 2006) . In ovarian cancer, several studies have reported genes that are differentially expressed in OCCC. However, there was little overlap among the genes identified in these studies, and thus a reproducible gene signature specific for OCCC has not yet been identified (Schwartz et al., 2002; Schaner et al., 2003; Tsuchiya et al., 2003; Marquez et al., 2005; Zorn et al., 2005) .
The primary purpose of this study is to identify the characteristic gene expressions that reproducibly distinguish OCCC among ovarian carcinomas, using microarray analyses for both clinical samples and cell lines. Next, by analyzing comprehensively the genes differentially expressed in OCCC, we sought for the unique gene groups or intracellular signaling that is relevant to the important clinical characteristics of OCCC. Third, we 
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Figure 1 Development and validation of the OCCC gene signature. In the GSE6008 data set, 5667 probes were differentially expressed between 8 OCCC and 91 non-OCCC tumors (a). In the KyotoOv38 data set, 884 probes were differentially expressed between 13 OCCC and 25 non-OCCC cell lines (b). The Venn diagram shows 437 overlapping probe sets (320 genes) from the clinical and cell line data sets (c). These 437 overlapping probe sets clearly detect OCCC-specific tumor clusters using hierarchical clustering within GSE6008 (d) and KyotoOv38 (e). In the analysis of the PMID16144910 data set (Marquez et al., 2005) , a tumor cluster containing six OCCC tumors was clearly detected using the OCCC signature (overlapping OCCC probe set) (f, left), whereas the nonoverlapping probe sets from GSE6008 (f, middle) and from KyotoOv38 (f, right) did not generate such a defined OCCC tumor cluster. For GSE2109, the overlapping OCCC signature generated gene clusters enriched for OCCC tumors (g, left) , whereas the nonoverlapping probe sets did not detect an OCCC-specific tumor cluster (g, middle and right). Hierarchical clustering of GSE4198 and GSE3001 using the 177 and 217 probe sets of the OCCC overlapping probes present on these arrays, respectively, generated OCCCspecific tumor clusters (h and i, respectively). Color bar at bottom of each heatmap represents histological subtype according to the legend, whereas the color bar to the right of each heatmap indicates increased (red) or decreased (green) expression.
Ovarian clear cell carcinoma signature and carcinogenesis K Yamaguchi et al show the potential role of microenvironment as well as epigenetic events in the induction of characteristic gene expressions of OCCC.
Results
Identification of ovarian clear cell carcinoma (OCCC) signature We used both clinical tissue samples and cell lines for identifying differentially expressed genes between OCCC and non-OCCC tumor cells. Among four publicly available microarray data sets of clinical samples, GSE6008 was used as the training set and PMID16144910, GSE2109 and GSE4198 as the external validation set independently. In the GSE6008 data set, 5667 U133A microarray probe sets were selected as differentially expressed between OCCC and non-OCCC tumors using significance analysis of microarrays (SAM) with a 5% false discovery rate q-value threshold ( Figure 1a ). We also analyzed 38 epithelial ovarian cancer cell lines (KyotoOv38) using microarray analysis (Supplementary Table 1 ). SAM identified 884 probe sets differentially expressed between OCCC and non-OCCC with the criteria of having a false discovery rate of o5% (Figure 1b) .
The Venn diagram (Figure 1c ) depicts the number of probe sets detected from both the clinical data set and the cell line data set. As expected, the 437 overlapping probe sets (393 upregulated and 44 downregulated), clearly detected the OCCC-specific tumor clusters using hierarchical clustering of GSE6008 ( Figure 1d ) and KyotoOv38 ( Figure 1e ). We designated these 437 probe sets (320 genes) as the 'OCCC signature', and the list of the probe sets comprising the OCCC signature is presented in Supplementary Tables 3a and b. Validation of ovarian clear cell carcinoma (OCCC) signature by other microarray data sets The reproducibility of the 437 overlapping probe sets in dividing OCCC and non-OCCC was verified using gene set enrichment analysis (GSEA; http://www.broad.mit. edu/gsea/) in the external data sets. Enrichment of these probe sets was analyzed individually in PMID16144910, GSE2109, GSE4198 and GSE3001. Consistent with expectations, OCCC upregulated genes were enriched among the OCCC specimens, and OCCC downregulated genes were enriched among the non-OCCC specimens in these data sets (Tables 1a and b, false discovery rate q-value of o0.05 for all).
We then examined the reproducibility of the pattern of up-or down-regulation of the OCCC probe sets using hierarchical clustering in the external data sets. We Ovarian clear cell carcinoma signature and carcinogenesis K Yamaguchi et al analyzed both the overlapping probe sets (the OCCC signature probe sets) and the non-overlapping probe sets that were identified in the independent analyses of the clinical specimens and cultured cells. As expected, in the analysis of the PMID16144910 data set, a tumor cluster was generated that contained six OCCC tumors by reproducing the pattern of increased or decreased expression of the overlapping OCCC probe sets (Figure 1f , left). The overall percentage of reproducibility of gene cluster classification was 97% (315/325). In contrast, when the probe sets selected from only the GSE6008 data set were used (non-overlapping), such a definite OCCC tumor cluster was not generated (Figure 1f , middle). When the probe sets selected from only KyotoOv38 were used (non-overlapping), cluster classifications for both tumors and genes did not reproduce the pattern of KyotoOv38 (Figure 1f , right). In the analysis of the GSE2109 data set, again, the 437 probe sets selected from both KyotoOv38 and GSE6008 (overlapping) generated gene clusters enriched for OCCC tumors with 95% (417/437) reproducibility of cluster classification of genes (Figure1g, left), whereas the non-overlapping probe sets that were only from GSE6008 or only from the KyotoOv38 did not detect an OCCC-specific tumor cluster ( Figure 1g , middle and Figure 1g , right, respectively). Furthermore, the other two complementary DNA-spotted microarray data sets, GSE4198 and GSE3001, were analyzed using genes corresponding to the U133A 437 probe sets selected from both GSE6008 and KyotoOv38 (overlapping). Hierarchical clustering of GSE4198 generated an OCCC-specific tumor cluster based on the OCCC upregulated and OCCC downregulated genes with 91% reproducibility of gene cluster classification (Figure 1h ). Hierarchical clustering of GSE3001 similarly generated an OCCC-specific tumor cluster with 85% reproducibility of gene cluster classification ( Figure 1i ). In summary, we found that at least 85% of the 320 genes (437 probe sets) selected from both GSE6008 and KyotoOv38 reproducibly generated OCCC-specific tumor clusters based on expression patterns of the OCCC upregulated and OCCC downregulated genes in the four external data sets. Using clinical samples, we also assessed whether the same 10 genes had higher expression in OCCC compared with non-OCCC. Semiquantitative RT-PCR showed that 8 of the 10 genes (Po0.05) were significantly upregulated in OCCC samples. The remaining two, ceruloplasmin and signal transducer and activator of transcription 3 (STAT3), also showed increased expression in OCCC, but the results for these genes were not statistically significant (P ¼ 0.1605 and P ¼ 0.1949, respectively; Figure 2b ).
The ovarian clear cell carcinoma (OCCC) signature is related to oxidative stress, cytokines, mitogen-activated protein kinase activity, coagulation and glycogen Categorical analysis of OCCC signature was performed using gene ontology (GO) term and transcription factor target analyses. We used allez, which determines the enrichment of a defined category by comparing the proportion of that category in the subset of genes analyzed with the proportion of that category in the genome. In the OCCC signature, 102 of the 825 terms GSEA was performed to determine whether the upregulated or downregulated gene sets comprising the OCCC signature are enriched in OCCC samples or non-OCCC samples using external data sets (GSE2109, GSE4198, GSE3001 and PMID16144910). The 393 upregulated probes, representing 282 genes ('OCCC Up Genes'), were enriched in OCCC (a), and the 44 downregulated probes, representing 38 genes ('OCCC Down Genes'), were enriched in non-OCCC (b).
in the GO 'biological process' (molecular signatures database c5.bp) (Supplementary Table 4a ), 34 of the 374 terms in the GO 'molecular function' (molecular signatures database c5.mf) (Supplementary Table 4b ) and 75 of the 615 categories in the 'transcription factor targets' (molecular signatures database c3.tft) (Supplementary Table 4c ) were significantly enriched when compared with the genome (cutoff P-value of o0.05).
Regarding the GO 'biological process' analysis, 4 of 5 oxidative-related terms, 10 of 11 stress pathwayrelated terms and 2 of 2 coagulation-related terms were significantly enriched in the OCCC signature (Po0.05 for all; Table 2a ). Similarly, in the GO 'molecular function' analysis, 5 of 10 glycogen-related terms were significantly enriched in the OCCC signature (P ¼ 0.0015; Table 2b ). For the analysis of 'transcription factor targets', the hepatocyte nuclear factor-1 (HNF-1) binding motif and 'activator protein 1-related categories' were significantly enriched in the OCCC signature (P ¼ 0.0002 and P ¼ 0.0009, respectively; Table 2c ).
The ovarian clear cell carcinoma (OCCC) signature includes molecular networks of hypoxia-inducible factor 1 (HIF-1a), interleukin-6 (IL-6), cyclin-dependent kinase inhibitor 1A and HNF-1b The characteristics of the OCCC signature were further evaluated by pathway and network analysis using Ingenuity pathways analysis (IPA; Ingenuity Systems, http://www.ingenuity.com). IPA identifies relevant pathways from a user input gene list, in this case the OCCC signature genes, and automatically draws networks between the established pathway genes and the list of input genes. Among the networks containing more than five genes, only one network, comprising 66 genes, was shown to be activated in the OCCC signature. The 66 genes in this network included HNF-1b, cyclindependent kinase inhibitor 1A (p21), HIF-1a, IL-6 and STAT3 (Figure 3a) . Thirteen canonical pathways were also included in this network. The most enriched canonical pathway was acute-phase response signaling (Po0.0001). Four glycogen-related pathways were also significantly enriched in this network (Figure 3b ).
The ovarian clear cell carcinoma (OCCC) signature is induced by exposure to the contents of endometriotic cysts or free iron to ovarian surface epithelium in a time-dependent manner As we previously suggested that cystic fluid in ovarian endometriosis contributes to the occurrence of OCCC, we determined whether the OCCC signature is induced by treatment with endometriosis contents. OSE/E7/hTERT cells were exposed to the contents of endometriotic cysts or free iron (Fe-NTA: 5 or 20 mM) for 1, 7 or 14 days, and gene expression levels were analyzed using the Affymetrix U133A 2.0 Array Ovarian clear cell carcinoma signature and carcinogenesis K Yamaguchi et al platform (Affymetrix, Santa Clara, CA, USA). We calculated an enrichment score that indicates if the OCCC signature is altered compared with the expression of other genes throughout the genome. If the OCCC signature is up-or down-regulated, the enrichment score will show a higher value. When OSE/E7/hTERT cells were exposed to endometriotic cyst contents, the enrichment scores showed an increase over a 14-day period. The scores were 0.114, 0.222 and 0.291 in one experiment and 0.107, 0.289 and 0.317 in another experiment for days 1, 7 and 14, respectively ( Figures  4a and b) . Similarly, when cells were treated with a low or high concentration of free iron, the enrichment scores were 0.091, 0.183 and 0.337 or 0.078, 0.274 and 0.320 for days 1, 7 and 14 in the first and second experiments, respectively (Figures 4c and d) .
The expression of the ovarian clear cell carcinoma (OCCC) signature is in part regulated by DNA methylation To further elucidate the mechanism by which the OCCC signature is regulated, the methylation status of representative genes in the OCCC signature, VCAN and HNF-1b, was evaluated semiquantitatively using the COmbined Bisulfite Restriction Analysis assay (Xiong and Laird, 1997) . When the cutoff methylation was set to 30%, none of the OCCC cell lines were methylated for VCAN in the MaeII digestion analysis, whereas five of eight non-OCCC cell lines were methylated (P ¼ 0.026, Figure 5a ). Similarly, none of the OCCC cell lines were methylated for HNF-1b, whereas all of eight non-OCCC cell lines were methylated (P ¼ 0.0014, Figure 5b ). (Sugiyama et al., 2000; Chan et al., 2008; Itamochi et al., 2008) , and therefore, an individualized modality of therapy against this disease is required. Advances in molecular characterization of histological types has allowed for development of targeted molecular therapies based on the specific subtype (Perou et al., 2000; van 't Veer et al., 2002) . To reveal the molecular background of OCCC, several microarray studies identified genes that are specifically expressed in OCCC (Schwartz et al., 2002; Schaner et al., 2003; Tsuchiya et al., 2003; Marquez et al., 2005; Zorn et al., 2005) . However, in each case only the respective original microarray data set was analyzed, and thus these reports did not test for reproducibility of the OCCC gene expression profiles that each defined. The aims of this research were to identify an OCCC gene signature, to verify its reproducibility in external data sets and to reveal the molecular background of OCCC through analysis of the OCCC signature genes. In the analysis of human clinical samples, contamination of non-tumor cells, such as stromal cells or immune cells, may hamper interpretation (Ramaswamy and Golub, 2002) . On the other hand, gene expression profiles of cell lines can be altered through the long-term in vitro culture of cells (Sandberg and Ernberg, 2005; Gibson, 2008) . Therefore, it is surmised that selecting genes whose expression patterns overlap in both cancer cell lines and tissue samples would potentially enhance the ability to identify genes that truly reflect the nature of the tumor cells. As there was no publicly available microarray data set of OCCC cell lines with a sufficient sample size, we generated a new microarray data set of 38 ovarian cancer cell lines containing 13 OCCCs. The 437 overlapping differentially expressed probe sets from both cell lines and cancer tissues ( Figure 1c) were then designated as comprising the OCCC signature. This overlapping probe set represents an unexpectedly large number of genes, given that they were selected from independent data sets with a strict criteria of having a false discovery rate q-value of o5%, indicating that patterns of differential gene expression that define OCCC are maintained in established cell lines and therefore likely reflect the underlying biological features of this subtype of ovarian cancer. As expected, GSEA analysis verified the enrichment of both upregulated and downregulated genes of the OCCC signature in multiple external data sets (Tables 1a and b) . Hierarchical clustering using the OCCC signature genes reproducibly identified OCCC-specific tumor clusters in four independent external data sets, whereas the non-overlapping probe sets from both the GSE6008 and KyotoOv38 data sets failed to detect OCCC-specific tumor clusters (Figure 1 ). These results suggest that the accuracy of the OCCC signature, which is reflected by the reproducible correct classification of OCCC specimens, was highly dependent on the selection of probe set genes using both cell lines and cancer tissues. This novel method may be useful for generating gene signatures for specific histological subtypes of other cancers or perhaps certain biological features such as chemosensitivity.
We then analyzed the biological properties of the genes included in OCCC signature. The signature contains several genes previously reported as OCCC markers, such as HNF-1b (Tsuchiya et al., 2003) , secreted phosphoprotein 1 (Kato and Motoyama, 2008) and HIF-1a (Lee et al., 2007; Osada et al., 2007) , again supporting that this signature is based on the selective extraction of a subset of biologically important and unique genes specific to OCCC. As shown in Tables 2a and b and Supplementary Tables 4a and b , genes categorized within the following GO term are significantly segregated in the OCCC signature: SUPEROXIDE_METABOLIC_PROCESS and RE-SPONSE_TO_OXIDATIVE_STRESS, which indicates oxidative stress; CYTOKINE_BIOSYNTHETIC_ PROCESS, which indicates inflammation; and POSITIVE_ REGULATION_OF_MAP_KINASE_ACTIVITY, which indicates an activated mitogen-activated protein kinase pathway, known as a stress signaling pathway. We have previously reported that epithelia in endometriotic cysts are exposed to significant and strong oxidative stress (Yamaguchi et al., 2008) . From this perspective, the results in this study suggest that the OCCC signature Ingenuity pathways analysis revealed that the OCCC signature contains a large gene network consisting of 66 genes, including HNF-1b, cyclin-dependent kinase inhibitor 1A (p21), HIF-1a, IL-6 and STAT3 (Figure 3a) . This result is consistent with the categorical analysis of activated transcription factors (Table 2c and Supplementary Table 4c ) that showed that 4 of 4 HNF-1 binding motifs and 9 of 22 activator protein-1-related motifs were included among 75 significantly enriched motifs, indicating that these signals have important roles in the biology of OCCC. Tsuchiya et al. (2003) also reported the overexpression of HNF-1b in OCCC and suggested that this molecule might be an OCCC-specific molecular marker (Tsuchiya et al., 2003) . Clinically, mutations of the HNF-1b gene result in maturity-onset diabetes of the young (Horikawa et al., 1997) . Mutations in the HNF-1b gene also cause various kidney malformations, suggesting that HNF-1b is important in kidney development (Zaffanello et al., 2008) . Together, these findings indicate that HNF-1b may be functionally associated with glycogen metabolism and renal morphogenesis. As OCCC is characterized by glycogen storage in the cytoplasm and morphological resemblance to renal cell carcinoma, HNF-1b may have an important role in manifesting these phenotypes, Figure 3 OCCC signature pathway analysis. Ingenuity pathways analysis identified a network activated in the OCCC signature, which consists of 66 genes including HNF-1b, CDKN1A (p21), HIF-1a, IL-6 and STAT3 (a). Thirteen canonical pathways are also included in this network, of which acute-phase response signaling is the most significantly enriched (Po0.0001). Four glycogen-related pathways are also significantly enriched in this network (b).
Ovarian clear cell carcinoma signature and carcinogenesis K Yamaguchi et al although the functional relevance of HNF-1 signaling and these features are yet to be elucidated. Network analysis also showed that the OCCC signature contains HIF-1a, IL-6 and STAT3 pathways, which are associated with hypoxia and inflammation, the known oncogenic signals. These analyses suggest that the OCCC signature is composed of genes that are clinically, pathologically and biologically important and compatible with known features of OCCC. First, it contains known oncogenic signals such as mitogen-activated protein kinase and activator protein-1. STAT3 pathway is especially implicated in the carcinogenesis associated with inflammation (Aggarwal et al., 2009b) , and HIF-1a also shares intracellular signaling with various oncogenes (Harris, 2002) , suggesting that these pathways have a part in the development of OCCC. On the other hand, oncogenes/ tumor suppressor genes, such as c-erbB-2, PTEN or p53, which are known to be involved in the carcinogenesis of other types of ovarian cancer, are not involved in OCCC signature, suggesting that OCCC has unique carcinogenic process. Second, OCCC signature contains genes associated with characteristic features of this malignancy. Increased expression of cyclin-dependent kinase inhibitor 1A (p21) may explain relatively slow growth of this tumor (Shimizu et al., 1999) . Actually, the transcriptional activity of NEGATIVE_REGULATIO-N_OF_CELL_PROLIFERATION is significantly activated in OCCC signature (Supplementary Table 4a ). Chemoresistance is another feature of OCCC. STAT3 and HIF-1a are reportedly associated with chemoresistance (Lau et al., 2009; Aggarwal et al., 2009a) . Annexin A4 (Zorn et al., 2005) , VCAN (Cattaruzza et al., 2004) and p21 (Hawthorne et al., 2009 ) may facilitate chemoresistance. It requires further evaluation of whether these gene expressions are really responsible for the biological behavior of OCCC.
We previously reported that contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of OCCC carcinogenesis through iron-induced persistent oxidative stress (Yamaguchi et al., 2008) . The results shown in this study also suggest that the OCCC signature reflects the microenvironment in which OCCC arise. To further elucidate this hypothesis, we tested whether the OCCC signature is induced by exposure to free iron or to the contents of endometriotic cysts. When immortalized ovarian surface epithelial cells were exposed to free iron or the contents of endometriotic cysts for 14 days, OCCC signature genes were predictably upregulated and downregulated in a time-dependent manner (Figure 4) . These results suggest that the in vivo environment, such as high iron or When OSE/E7/hTERT cells were exposed to contents from two different endometriotic cyst (a, b) and Fe-NTA 5 mM or 20 mM (c, d, respectively), OCCC enrichment scores increased over a 14-day period. The vertical axis shows the enrichment score and the horizontal axis shows the log ratio rank of expression for the OCCC signature genes. Black line, day 1; red line, day 7; green line, day 14.
Ovarian clear cell carcinoma signature and carcinogenesis K Yamaguchi et al other components present in endometriotic cysts, are closely associated with the OCCC signature. Previous reports have indicated that the risk of ovarian cancer is elevated in women with a long-standing history (410 years) of ovarian endometriosis (Brinton et al., 1997) . The OCCC signature presented in this study is not only a specific and reproducible marker, but also represents the biological response occurring during the OCCC carcinogenic process. In other words, our genome-wide analysis of OCCC-specific gene expression shows the possibility, for the first time, that environmental factors and the specific carcinogenic process determine the pathological phenotypes of the carcinoma and its unique gene expression profile. One important issue is that although the OCCC signature is passively induced in vitro by treatment with endometriotic cyst fluid, it is constitutively expressed in established OCCC cell lines under ordinary culture conditions, suggesting that genetic or epigenetic events may happen in the developmental process of OCCC. To examine this possibility, we analyzed whether DNA methylation status is associated with the expression of the OCCC signature. Analyses of two representative OCCC signature genes, VCAN and HNF-1b, showed that methylation was not detected in OCCC cells, whereas it is often observed in non-OCCC cell lines, suggesting that at least some genes in the OCCC signature are epigenetically regulated ( Figure 5 ). Genome-wide hypomethylation can cause genomic instability and, consequently, tumor formation (Ushijima, 2005) . Our results suggest that aberrant methylation status in the carcinogenic environment contributes to the etiology of OCCC, although the mechanism is not yet understood.
In summary, we identified a gene expression signature specific for OCCC by extracting overlapping genes in microarray data sets of both clinical samples and established ovarian cancer cell lines. This OCCC signature contains genes previously shown to characterize OCCC, and reproducibility predicts OCCC specimens in many other microarray data sets. The OCCC signature was induced by treatment of ovarian surface epithelial cells with the contents of endometriotic cysts, revealing a possible link between this signature and the carcinogenic environment of OCCC. The expression of OCCC signature genes was, at least in part, epigenetically regulated. This genome-wide gene profile study describes for the first time the possibility that the carcinogenic environment induces specific gene expression profiles and contributes to the development of pathological subtypes of cancer.
Materials and methods

Patients and tissue samples
Tissue specimens were derived from 16 patients with ovarian cancer treated at Kyoto University Hospital, all of whom provided informed consent under permission of the ethical committee of the hospital. Tumors were histologically classified according to the World Health Organization criteria.
Cell lines and preparation of total RNA and genomic DNA The immortalized ovarian surface epithelial cell line (OSE/E7/ hTERT) was kindly provided by Dr Katabuchi at Kumamoto University (Maeda et al., 2005) . Ovarian cancer cell lines, including 13 OCCC and 25 non-OCCC cell lines (Supplementary Table 1 ), were designated as KyotoOv38 and cultured in RPMI-1648 (Nikken Bio Medical Laboratory, Kyoto, Japan) supplemented with penicillin-streptomycin and 10% fetal bovine serum. Total RNA was isolated from cells at 70-90% confluency or from 200-300 mg of tissues using the RNeasy Mini Kit (Qiagen K.K., Tokyo, Japan). Genomic DNA was prepared using the QIAamp DNA mini kit (Qiagen K.K.).
Microarray data sets
Microarray analyses were performed using Affymetrix Human Genome U133A 2.0 Arrays following standard Affymetrix protocols at the Duke Microarray Facility, Duke University. The expression intensities across the samples were normalized using the robust multichip average algorithm (Irizarry et al., 2003) .
Four microarray data sets of ovarian clinical samples and one microarray data set of ovarian cancer cell lines that included clear cell and serous subtypes were obtained from publicly available databases online (see Supplementary Materials and methods). In this study we refer to the microarray data sets by Gene Expression Omnibus accession number and/or by the PubMed Identifier number.
Reverse transcriptase-PCR (RT-PCR)
Quantitative RT-PCR (qRT-PCR) was performed using 50 ng of total RNA from 16 ovarian cancer cell lines using primer sets specific for VCAN (Assay ID: Hs00171642_m1) and control glyceraldehyde-3-phosphate dehydrogenase (Part number: 402869) (TaqMan Gene Expression Assays; Applied Biosystems, Foster City, CA, USA). Relative expression levels of annexin A4, ceruloplasmin, FXYD2, HIF-1a, HNF-1b, IL-6, superoxide dismutase 2, secreted phosphoprotein 1, STAT3 and VCAN were obtained semiquantitatively by normalization to the expression levels of glyceraldehyde-3-phosphate dehydrogenase by densitometry using Image J 1.33u. Primer sequences are provided in Supplementary Table 2 .
Methylation analysis using Combined bisulfite restriction analysis The methylation status of two genes (VCAN and HNF-1b) was evaluated semiquantitatively using the combined bisulfite restriction analysis assay, as previously described (Xiong and Laird, 1997) . In brief, the bisulfite conversion of 0.5 mg of genomic DNA was performed using an EpiTect Bisulfite Kit (Qiagen K.K.). PCR was preformed as previously described (Issa et al., 2001 ) and the products were digested with the enzymes MaeII and Taq a I for VCAN and TaiI for HNF-1b.
Bioinformatics methodologies (details are shown in Supplementary Materials and methods) Identification of differentially expressed genes between OCCC and non-OCCC was performed by comparing gene expression profiles using SAM (Tusher et al., 2001) . Genes selected by SAM were used to conduct average-linkage hierarchical clustering with Cluster version 3.0. (http://rana.lbl.gov/eisen/). Heatmaps and dendrograms were generated with Java Tree View (http://jtreeview.sourceforge.net/)
. GSEA was performed to analyze the enrichment of the gene sets . To evaluate the enrichment of the OCCC signature for genes induced by oxidative stress, we generated an enrichment score as defined by GSEA procedures (Sweet-Cordero et al., 2005) . The biological characteristics of the OCCC signature were evaluated by the enrichment of molecular signatures database gene sets (v2.5 updated 7 April 2008) using the R package allez 1.0 . A gene set was considered significantly enriched if the nominal P-value was o0.05 (Pyeon et al., 2007) . IPA is a commercial application that calculates the association between a particular gene set and known pathways. The activated pathways in OCCC were searched using IPA software with filtering of 'Human' and 'Relax Relation (including Indirect)'.
Statistical analysis
The Mann-Whitney U test with Bonferroni correction was used to compare the expression levels of OCCC, determined using RT-PCR analyses, with those of non-OCCC. Fisher's exact test was used for analysis of contingency tables. The correlation between the expression values in the KyotoOv38 microarray data sets and those determined from semiqRT-PCR or qRT-PCR was evaluated using Spearman's correlation. A P-value of o0.05 was considered statistically significant.
